Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Point-of-Care HIV Testing and Early Dolutegravir Use for Infants
NCT05393193Phase 4Active, not recruiting
- Sponsor
- Harvard T.H. Chan School of Public Health
- Start
- Jul 2022
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dolutegravir in human immunodeficiency virus infection (HIV), sponsored by Harvard T.H. Chan School of Public Health. Started Jul 2022; status: active, not recruiting.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05393193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05393193.